Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 285 participants.
Also called NCT07282743
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 285 participants
- Sponsor
- Sun Pharmaceutical Industries Limited
- Registry
-
NCT07282743
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, India
- Registry status
- Recruiting
Technical summary
Registry record NCT07282743. Randomized; triple masking; primary purpose treatment. Start 2026-01-20 (actual); primary completion 2027-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
- Condition
- Type II Diabetes Mellitus
- Intervention (Drug)
- GL0034 Dose Level 1
- Intervention (Drug)
- GL0034 Dose Level 2
- Intervention (Drug)
- GL0034 Dose Level 3
- Intervention (Drug)
- GL0034 Dose Level 4
- Intervention (Drug)
- GL0034 Dose Level 5
- Intervention (Drug)
- GL0034 Dose Level 6
- Intervention (Other)
- Placebo
- Lead sponsor
- Sun Pharmaceutical Industries Limited
Record details
- Record id
cardio:ct-nct07282743- Content hash
776ff6194bdf547b595f5d9d8fec9d36e5c619b826467e483ca7bc29c83023c2